CeMines to Sell Research Tools Business

An announcement from the company has confirmed the intent of CeMines (Golden, CO, USA) to sell its multi-million-dollar inventory of polyclonal antibodies (cDNA and mRNA). The business also includes associated trademarks and a multinational customer base that includes well-known research institutions.

CeMines entered the research tools business in 2001 to advance its cancer-diagnostics product development and drug discovery research. Its strategy then was to focus on complete families of a limited number of antibodies, hence the large inventory. The company noted that multiple offers have been made for its research tools business, and pro forma bids are being reviewed. Roger Attick, president and CEO of CeMines, said a final decision is likely before the end of the year.

"In this environment, a new upstart research tools company can scale literally overnight, or a larger provider could add substantial depth and round out its existing inventory,” noted Mr. Attick. The company is hoping to soon receive the CE Mark for its CellCorrect product family in Europe. "Considering all the outsider speculation that this event will occur soon, we are not surprised by the substantial interest in our research tools business and product inventories,” he added.

CeMines is specializing in cell systems biology and regulatory network research and development to commercialize clinical products for worldwide use in diagnosing and treating cancer.






Related Links:
CeMines